

**III. Claim Amendments under 37 C.F.R. § 1.121**

1-11. (Canceled)

12. (New) An adenovirus vector comprising a recombinant expression vector comprising one or more enhancers linked to the 5' end of a ubiquitin promoter operably linked to a DNA sequence encoding a therapeutic transgene.

13. (New) The adenovirus vector of claim 12, wherein the ubiquitin promoter is isolated from a gene selected from the group consisting of human ubiquitin A, ubiquitin B, and ubiquitin C.

14. (New) The adenovirus vector of claim 12, wherein the enhancer is selected from the group consisting of cytomegalovirus (CMV) enhancer, an elongation factor 1-alpha enhancer, endothelial enhancers, and liver-specific enhancers.

15. (New) The adenovirus vector of claim 14, wherein the enhancer is a CMV enhancer.

16. (New) The adenovirus vector of claim 14, wherein the ubiquitin promoter is isolated from human ubiquitin B.

17. (New) The adenovirus vector of claim 12, wherein the therapeutic gene is selected from the group consisting of Factor VIIa, Factor VIII, and Factor IX.

18. (New) The adenovirus vector of claim 12, wherein the therapeutic gene is selected from the group consisting of glucocerebrosidase, alpha-galactosidase, acid alpha-glucosidase, alpha-n-acetylgalactosaminidase, acid sphingomyelinase, and alpha-iduronidase.

19. (New) The adenovirus vector of claim 12, wherein the therapeutic gene is selected from the group consisting of CFTR, dystrophin, and alpha-1-antitrypsin.

20. (New) An adenovirus vector comprising a recombinant expression vector comprising a CMV enhancer linked to the 5' end of a promoter isolated from human ubiquitin B operably linked to a DNA sequence encoding alpha-galactosidase.

21. (New) An adenovirus vector comprising a recombinant expression vector comprising a CMV enhancer linked to the 5' end of a promoter isolated from human ubiquitin B operably linked to a DNA sequence encoding glucocerebrosidase.


22. (New) An adenovirus vector comprising a recombinant expression vector comprising one or more enhancers linked to the 5' end of a ubiquitin promoter operably linked to a DNA sequence encoding a therapeutic transgene.
23. (New) The adeno-associated virus vector of claim 22, wherein the ubiquitin promoter is isolated from a gene selected from the group consisting of human ubiquitin A, ubiquitin B, and ubiquitin C.
24. (New) The adeno-associated virus vector of claim 22, wherein the enhancer is selected from the group consisting of cytomegalovirus (CMV) enhancer, an elongation factor 1-alpha enhancer, endothelial enhancers, and liver-specific enhancers.
25. (New) The adeno-associated virus vector of claim 24, wherein the enhancer is a CMV enhancer.
26. (New) The adeno-associated virus vector of claim 24, wherein the ubiquitin promoter is isolated from human ubiquitin B.
27. (New) The adeno-associated vector of claim 22, wherein the therapeutic gene is selected from the group consisting of Factor VIIa, Factor VIII, and Factor IX.
28. (New) The adeno-associated vector of claim 22, wherein the therapeutic gene is selected from the group consisting of glucocerebrosidase, alpha-galactosidase, acid alpha-glucosidase, alpha-n-acetylgalactosaminidase, acid sphingomyelinase, and alpha-iduronidase.
29. (New) The adeno-associated vector of claim 22, wherein the therapeutic gene is selected from the group consisting of CFTR, dystrophin, and alpha-1-antitrypsin.
30. (New) An adeno-associated vector comprising a recombinant expression vector comprising a CMV enhancer linked to the 5' end of a promoter isolated from human ubiquitin B operably linked to a DNA sequence encoding alpha-galactosidase.
31. (New) An adeno-associated vector comprising a recombinant expression vector comprising a CMV enhancer linked to the 5' end of a promoter isolated from human ubiquitin B operably linked to a DNA sequence encoding glucocerebrosidase.

#### IV. Conclusion

No fee is deemed necessary in connection with the filing of this communication. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 07-1074.

8/26/07  
Date

Respectfully submitted,



Jennifer D. Tousignant  
Agent for Applicants  
Registration No. 54,498  
Telephone: (508) 270-2499  
Facsimile: (508) 872-5415

GENZYME CORPORATION  
15 Pleasant Street Connector  
P.O. Box 9322  
Framingham, Massachusetts 01701-9322